NCT04436133 - Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | Biotech Hunter

Enrollment

480

Participants

Timeline

Start Date

June 20, 2020

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions

HPV InfectionHPV-Related Cervical Carcinoma

Interventions

BIOLOGICAL

Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle

BIOLOGICAL

9-valent HPV vaccine（Gardasil 9）

Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle

Trial Locations (1)

Liucheng Center for Disease Control and Prevention, Liuzhou

All Listed Sponsors

collaborator

Chengdu Institute of Biological Products Co.,Ltd.

INDUSTRY

collaborator

Simoon Record Pharma Information Consulting Co., Ltd.

INDUSTRY

collaborator

Guangxi Center for Disease Control and Prevention

OTHER_GOV

collaborator

Beijing Kantorico Statistical Technology Co., Ltd.

UNKNOWN

lead

National Vaccine and Serum Institute, China

INDUSTRY